Chairperson: Andy Minn, MD, PhD, Memorial Sloan Kettering Cancer Center

12:25 PM

Histotripsy Combined with Innate Immune Activation Reprograms the Pancreatic Tumor Microenvironment and Drives Systemic Anti-Tumor Immunity 

Tamalika Paul, MS, Virginia Tech 

12:40 PM

Humoral IgG1 Responses to Tumor Antigens Underpin Clinical Outcomes in Immune Checkpoint Blockade 

Edgar Gonzalez-Kozlova, PhD, Icahn School of Medicine at Mount Sinai 

12:55 PM

Optimizing Targeted Therapy Regimens to Enhance the Efficacy of Combinatorial Immunotherapy in KRASG12C-Mutated Lung Cancer 

Mineyoshi Sato, MD, PhD, Weill Cornell Medicine